PD-1 and PD-L1 Immunotherapy Market Growth, Trends, and Forecasts (2020-2026)

Globalmonitor

Globalmonitor

Global PD-1 and PD-L1 immunotherapy market was estimated to reach 51.35 billion by 2024. The market is expected to grow at a CAGR of 10.54% from 2020 to 2028.

SEATTLE, WASHINGTON, UNITED STATES, December 3, 2020 /EINPresswire.com/ — Market Overview
The global PD-1/PD-L1 immunotherapy market is undergoing a significant flux with regard to the advancements that have already taken place and are currently surging in the market. Additionally, with the increase in the prevalence of cancer and expedited approvals by drug regulatory bodies the market is expected to propel at a faster rate. This chapter reviews the significant drivers and restraints that are considerably impacting the dynamicity of the global PD-1/PD-L1 immunotherapy market.

Various companies are developing PD-1 and PD-L1 inhibitor drugs using ground breaking techniques, such as combination therapy and biomarkers. In combination therapy, PD-1 and PD-L1 inhibitors combine with different type of molecules such as monoclonal antibodies, small molecule, vaccines, and cell therapies. The two therapies when administered together are more effective as compared to single immunotherapy. This will substantially drive the growth of the global PD-1 and PD-L1 inhibitors market.

Based on type, the global PD-1/PD-L1 immunotherapy market has been divided into two segments namely Programmed Death 1 (PD-1) and Programmed Death Ligand 1 (PD-L1). The PD-1 segment currently dominates the global PD-1/PD-L1 immunotherapy market and is anticipated to remain dominant during the forecast period due to rise in adoption of pembrolizumab (keytruda) and nivolumab (opdivo) and wide range of indications covered by the PD-1 inhibitors.

Request overview report @ https://www.globalmonitor.us/product/pd-1-and-pd-l1-immunotherapy-market

Market Dynamics
Increasing Prevalence of Cancer, large unmet needs in the market, growing advancements in the field of precision medicine sector and increasing awareness among people for the treatment of cancer are the market factors driving the growth of the market in the forecasted period.

Adverse effects of immunotherapy, high cost of treatment, reimbursement issues, and high cost of development of new therapies are the major factors challenging the growth of the market.

Segmentation by Application
Based on application, the global PD-1/PD-L1 immunotherapy market has been divided into seven segments, namely non-small cell lung cancer (NSCLC), multiple myeloma, hepatocellular carcinoma, esophageal cancer, small cell lung cancer, gastric cancer, head and neck cancer, and others. The NSCLC segment currently dominates the global PD-1/PD-L1 immunotherapy market and is anticipated to remain dominant during the forecast period due to rise in prevalence of non-small cell lung cancer, overall survival benefit with the PD/PD-L1 inhibitors, and prolonged survival with the PD- 1/PD-L1 inhibitors along with combination of other drugs.

The majority of progress in PD-1/PD-L1 has been in the field of non-small cell lung cancer. However, the pipeline analysis and clinical trial analysis of the major players in the market show the changing market. Various players are conducting clinical trials with their products to fill the unmet medical need and are trying to find a better treatment modality in the niche cancers, for which a standard of care is not available as of yet.

Request overview report @ https://www.globalmonitor.us/product/pd-1-and-pd-l1-immunotherapy-market

Segmentation by Geography
The market potential of the global PD-1/PD-L1 immunotherapy market with respect to different regions, namely North America, Europe, Asia-Pacific (APAC), Latin America (LATAM), and Rest-of- the-World (RoW), has been described in this section. The section also comprises country-level analysis of the market, along with the key factors responsible for market growth. This chapter analyzes the ongoing trends in the industry in major geographical regions by probing into the past and the present government regulations and the macro-and micro-economic factors.

The high demand for PD-1/PD-L1 immunotherapy in North America is largely attributed to the rising prevalence of cancer, increasing research and development in the U.S., and the presence of a majority of companies in the U.S.

The North America PD-1/PD-L1 immunotherapy market is foreseen to be majorly driven by the growing need to develop novel cancer therapeutic options for the treatment of advanced cancers, coupled with the rise in biopharmaceutical research and development expenditure. Additionally, increasing awareness amongst cancer patients pertaining to the probability of cancer survival, accompanied with the advancements in the field of oncology through the implementation of precision medicine, has further augmented the growth of the North America PD-1/PD-L1 immunotherapy market. Moreover, FDA has been regulating the guidelines for faster approval of these drugs which are likely to improve the healthcare status.

Request overview report @ https://www.globalmonitor.us/product/pd-1-and-pd-l1-immunotherapy-market

Competitive Landscape
Merck & Co., Inc. currently dominates the global PD-1/PD-L1 immunotherapy market. In 2019, the company registered a market share of 50.36%, a 3.80% increase from 2018 (46.56% market share). The company sustains its dominant position in the market owing to excellent performance by Keytruda in the U.S. and international markets and its approvals for the greatest number of indications in the market.

Bristol Myers Squibb Company currently holds the second largest share in the global PD-1/PD-L1 immunotherapy market. In 2019, the company registered 32.73% market share. However, it has been observed that the company’s share decreased from 43.73% in 2018 to 32.73% in 2019. The reduction in market share, is predominantly attributed to the cannibalization of its market by Keytruda, and failure in various clinical trials. The other companies segment includes Sanofi S.A., Regeneron Pharmaceuticals Inc., AstraZeneca Plc, Pfizer Plc, Merck KGaA, and F. Hoffmann-La Roche Ltd.

Bhanu Reddy
Global Monitor
+1 206-809-0882
email us here
Visit us on social media:
Twitter
LinkedIn


Source: EIN Presswire

Non-invasive Prenatal Testing (NIPT) Market Growth, Trends, and Forecasts (2020-2026)

Globalmonitor

Globalmonitor

Global NIPT market is dominated by cfDNA that held a volume of 2.89 million units in 2019 and is expected to reach 19.54 million units in 2030.

SEATTLE, WASHINGTON, UNITED STATES, December 3, 2020 /EINPresswire.com/ —
Market Overview
With the advancements in genomic technologies such as gene-editing technology, biomarkers, and next-generation sequencing, the demand for early diagnosis of genetic diseases has increased. This advancement has further enhanced the potential of NIPT and the possibility of a diagnosis of genetic disorders before birth. The global NIPT market has been identified as one of the fastest emerging industries, owing to the changing dynamics of the legal and regulatory framework and the intense competitive rivalry among an array of public companies. The acceptance of NIPT as an essential prenatal test is regarded as one of the most noteworthy changes in the prenatal testing industry because of its capability to provide early diagnosis of various genetic disorders, such as Down’s syndrome, Edwards’ syndrome, and Patau’s syndrome.

Market Dynamics
Growing emphasis on early detection and prevention, presence of advanced screening technologies, increasing consumer demand, growing incidence of Down’s Syndrome, increasing average maternal age, and growing prevalence of genetic and congenital disorders are the key factors driving the growth of the market.

Stringent regulatory guidelines, limitations of NIPT testing, lack of awareness among consumers, and presence of alternative screening & testing methods are the major factors restraining the growth of the market.

Request overview report @ https://www.globalmonitor.us/product/non-invasive-prenatal-testing-market

Segmentation by Test Type
The NIPT industry is gaining traction owing to the flourishing growth of gene sequencing and analytical tools, integration of smart technologies into healthcare, collaborations of healthcare, and IT firms with pharmaceutical and biotechnology companies, and increasing government investments in its research and development initiatives. NIPT is one of the most modernized trends in the healthcare industry and has shown a tremendous progress in the last few years.

The global NIPT market, by test type, is largely dominated by Panorama and Vistara, contributing 9.77% of the total market share in 2019. Both of these tests are offered by Natera, Inc. The growth can be accounted to the extensive analysis of single nucleotide polymorphisms (SNP) using the Natera’s next-generation aneuploidy testing using SNPs (NATUS) technology. However, among all the tests, Bambni Test offered by Berry Genomics is expected to witness the highest CAGR during the forecast period, 2020-2030.

Panorama prenatal test was globally launched in March 2013, by Natera, Inc. for the detection of chromosomal aneuploidies, such as trisomies (21, 18, and 13) and Monosomy of X chromosome. This test is based on the extensive analysis of SNP and analyzes around 19,500 SNPs in a single reaction using its proprietary NATUS technology. In October 2013, Natera, Inc. expanded the test menu of Panorama by adding triploidy detection.

Segmentation by Method
Prenatal tests have evolved in terms of high safety and accuracy, and cost-effectiveness, to accelerate prenatal testing and reduce the global burden of genetic disorders. The largest share of cfDNA can be accredited to its promising potential to revolutionize the diagnosis and treatment of several medical conditions, including NIPT, oncology screening and monitoring, and post transplantation monitoring, among others. On the other hand, FCMB accounted for 23.30% of the global NIPT market share in 2019. The growth can be accredited to the ease of use cfDNA and safety and accuracy associated with cfDNA- based NIPTs.

Request overview report @ https://www.globalmonitor.us/product/non-invasive-prenatal-testing-market

Segmentation by Geography
The NIPT market has developed quite massively in the developed regions of North America and Europe but is currently at a nascent stage and is underpenetrated in several countries of Asia-Pacific and Latin America. Advantages of NIPT, such as no risk of miscarriage and high accuracy of the procedure, are the major factors contributing to the growth of the NIPT market in North America, Europe, and Asia-Pacific. Japan, China, Australia, and India are the major countries in Asia-Pacific that offer immense opportunities to companies operating in the market.

Asia-Pacific is the fastest-growing region of the global NIPT market and is expected to register the highest CAGR during the forecast period 2020-2030, in terms of revenue and volume. Several conglomerate and small-medium enterprises are focused on collaborating with each other and other distributing channels to expand their global reach, thus consequentially promoting the growth of the global NIPT market by region.

The presence of good healthcare infrastructure, and large number of well-established diagnostic centers and hospitals offering NIPT services in North America are some of the factors that lead to the dominance of North America in the global NIPT testing market. Furthermore, North America is home to several NIPT manufacturers as well as service providers, and availability of reimbursement coverage are driving the growth of the market value. Moreover, extensive deal of research activities happening in the field of NIPT and growing awareness related to prenatal testing, is further contributing to its market growth.

Request overview report @ https://www.globalmonitor.us/product/non-invasive-prenatal-testing-market

Competitive Landscape
Among the different companies, Natera, Inc. was the leading player of the global NIPT market and dominated the market in 2019. The company accounted for 9.70% of the global market share in 2019. The company’s market dominance is attributed to the broad range of NIPT solutions that it is offering in this market and the massive demand for the company’s product lines. In addition, the competitive strategies adopted by the company in the past four years also contributed to its market share.

Following Natera, Inc., Laboratory Corporation of America Holdings (LabCorp) and Eurofins Scientific were the second and third major contributor of the global market revenue, accounting 9.68% and 9.67% of the total market share in 2019, respectively. Illumina, Inc., followed by F. Hoffmann-La Roche Ltd, were the fourth and fifth major contributors, respectively. The other companies holding significant market share in the global NIPT market were Quest Diagnostics Incorporated, BGI, Myriad Genetics, Inc., PerkinElmer Inc., Yourgene Health PLC, and Berry Genomics, among others.

Bhanu Reddy
Global Monitor
+1 206-809-0882
email us here
Visit us on social media:
Twitter
LinkedIn


Source: EIN Presswire

Cancer Immunotherapy Market Growth, Trends, and Forecasts (2020-2026)

Globalmonitor

Globalmonitor

The global cancer immunotherapy market was estimated to reach 178.70 billion by 2028. The market is expected to grow at a CAGR of 14.23% from 2020 to 2028.

SEATTLE, WASHINGTON, UNITED STATES, December 3, 2020 /EINPresswire.com/ —
Market Overview
Monoclonal antibodies are specific types of antibodies engineered in laboratories. These monoclonal antibodies attach to specific proteins and destroy cancer cells. Other types of antibodies function as check point inhibitors which act on the immune check points and block these pathways. This allows the immune system to identify and respond to cancer cells. Oncolytic virus therapy involves injecting genetically modified viruses into cancer cells. The virus multiplies within the cells and ultimately causes them to burst. Cancer vaccines are also being developed and commercialized to help the immune system fight against cancer by triggering immune response against vaccine antigen.

Market Dynamics
The global cancer immunotherapy market is affected both positively as well as negatively by various factors. Some of the key factors impacting the cancer immunotherapy market are:

Market Drivers

· Rising Prevalence of Cancer

· Unmet Medical Needs of Cancer Patients

· Rising R&D Expenditure in Oncology Field •Advancements of Precision Medicine in Immuno-Oncology

· Development of Targeted Therapy

· Developing Healthcare Infrastructure and Reimbursement

Restraints

· High Cost of Treatment

· Adverse Effects of Cancer Immunotherapy

Request overview report @ https://www.globalmonitor.us/product/cancer-immunotherapy-market

Segmentation by Product
Cancer immunotherapy involves therapies or products that stimulate and boost the immune system of the human body.

The global market for cancer immunotherapy was dominated by the monoclonal antibodies with a share of 66.50% in 2020. The fastest growing segment was estimated to be check point inhibitors.

The first monoclonal antibody against cancer, known as Rituximab, was approved for clinical use in 1997. A number of monoclonal antibodies for cancer therapeutics have been approved by the FDA over the years. Several types of monotherapies including naked, conjugated and bispecific MAbs are now being used

Monoclonal antibodies are increasingly being adopted for treatment due to their targeted approach and ability to identify and bind to tumor cells. Owing to their proven efficacy and safety, biopharmaceutical companies are investing significantly into their development.

Request overview report @ https://www.globalmonitor.us/product/cancer-immunotherapy-market

Segmentation by Geography
North America currently dominates the cancer immunotherapy market, which is enormously driven by the rising incidence of different types of cancers, growing geriatric population, technological advancement in new drug discovery and support of the government regulations.

North America comprises of the U.S. and the Canadian market. Currently, the U.S. accounts for the largest share because of extensive investments for research and discovery of better oncology drugs by government organizations and pharmaceutical companies

The development of immunotherapy for cancer treatment has also gained popularity in Europe. The European countries have fastened their process of reimbursing immunotherapies due to the pan- tumor agreements that have been implemented. These agreements extend over multiple indications over multiple years and hence are referred to as Multi-Year-Multi-Indication (MYMI) agreements. They are a result of partnership between policymakers and companies and have resulted in significant reduction in the reimbursement approval times. For Belgium, the reimbursement approval time has changed from 411 days to 30 days, Denmark has had it changed from 155 days to 60 days. Reimbursement in Belgium for immunotherapies has been fast-tracked through accelerated reimbursement procedures.

Request overview report @ https://www.globalmonitor.us/product/cancer-immunotherapy-market

Cancer has become an increasingly difficult to tackle health problem in the Asia-Pacific region. Many of the low- and middle- income countries in the Asia Pacific regions are witnessing a constant increase in the cancer incidence. Ageing populations, changes in lifestyle, increased exposure to cancer causing mutagens and other genetic factors, are some of the common risk factors associated with economic development and epidemiologic transition of the Asia-Pacific region

Competitive Landscape
Cancer immunotherapy is rapidly gaining momentum in the oncology treatment market. The improved efficacy and less toxicity of the treatment has increased the market penetration for cancer immunotherapy. The market was dominated by F.Hoffmann La-Roche with a share of 59.68% in 2019. The company has been a leader in the oncology treatment market for a long time and has a robust pipeline for oncology diseases. Moreover, the company offers a variety of monoclonal antibodies and check point inhibitors for cancer immunotherapy. Another monoclonal antibody, Arzerra has been approved for Chronic Lymphocytic Leukemia (CLL).

Bhanu Reddy
Global Monitor
+1 206-809-0882
email us here
Visit us on social media:
Twitter
LinkedIn


Source: EIN Presswire

Global Soy & Dairy Protein Ingredient Market Industry Analysis, Size, Share, Growth, Trends and Forecast 2020-2026

WiseGuyReports.com adds “Global Soy & Dairy Protein Ingredient Market Research Report 2020 Analysis and Forecast 2026” reports to its database.

PUNE, MAHARASTRA, INDIA, December 3, 2020 /EINPresswire.com/ — Soy & Dairy Protein Ingredient Market:

Executive Summary

The global Soy & Dairy Protein Ingredient market report highlights the various facets of the industry while maintaining its unbiased view. The study reveals a possibility for the market to experience a stupendous CAGR during the forecast period of 2020 to 2026. The detailed analysis takes into consideration the factorial discussions, trends and opportunities, and threats. The segmentation of the report and the regional prospects of the market make it easy reading for the user. Data science and artificial intelligence are being employed to gather data rapidly. Competitive intelligence and profiling of key players can help readers in navigating the Soy & Dairy Protein Ingredient market with ease.

Market Dynamics

A proper understanding of the Soy & Dairy Protein Ingredient market dynamics and their inter-relations helps in gauging the performance of the industry. The growth and revenue patterns can be revised and new strategic decisions taken by companies to avoid obstacles and roadblocks. It could also help in changing the patterns using which the market will generate revenues. The analysis includes an assessment of the production chain, supply chain, end user preferences, associated industries, proper availability of resources, and other indexes to help boost revenues.

Get Sample Copy of the Report @ https://www.wiseguyreports.com/sample-request/6089325-global-soy-dairy-protein-ingredient-market-research-report-2020

Segmentation

Market analysts, who have shown an interest in understanding the Soy & Dairy Protein Ingredient market, have segmented the market. This review encourages a look at the market from several scientific points of view based on volume, value, chart, graph, factor, and others. The value and growth rate are specified and backed by accurate drivers and hurdles.

Regional Analysis

The global Soy & Dairy Protein Ingredient market analysis reveals a detailed examination of regional challenges to understand several demographic changes. This type of understanding of the market would provide better knowledge regarding the growth pockets where cultural preferences, channelizing of resources, inspiring market demands, understanding of various market possibilities, and others can reveal aspects that, when nurtured, would provide outstanding results. This region-specific reading of the market includes West and East Europe and an analysis of the challenges faced in both these areas, prospects in several emerging countries from the Asia Pacific region, changing market dynamics of North and South America, and a proper survey of countries from the Middle East & Africa. It will help in assessing various growth opportunities in the coming years.

Competitive Analysis:

Key players of the Soy & Dairy Protein Ingredient market are profiled and their strategies studied for a better playing field. Case studies of successful products, alliances and mergers, and financial sheets are analyzed to discern their success and throwbacks. Government policies, subsidies and incentives, and consumer response are metrics which are studied with regards to the market.

Market Key Player

ADM
Cargill
Bunge
Fonterra
Mead Johnson
CHS
Lactalis Ingredients
Dairy Farmers of America
Arla Food Ingredients
Glanbia Ingredients
Valio
Alpavit
DuPont
Kerry
Wilmar International
Nisshin Oillio
Ag Processing
Devansoy
Biopress
Kellogg
Doves Farm Foods
Kraft
Foremost Farms
DMK
Axiom

Table of Content

1 Soy & Dairy Protein Ingredient Market Overview

2 Global Soy & Dairy Protein Ingredient Market Competition by Manufacturers

3 Soy & Dairy Protein Ingredient Retrospective Market Scenario by Region

4 Global Soy & Dairy Protein Ingredient Historic Market Analysis by Type

5 Global Soy & Dairy Protein Ingredient Historic Market Analysis by Application

6 Company Profiles and Key Figures in Soy & Dairy Protein Ingredient Business

7 Soy & Dairy Protein Ingredient Manufacturing Cost Analysis

8 Marketing Channel, Distributors and Customers

9 Market Dynamics

10 Global Market Forecast

11 Research Finding and Conclusion

12 Methodology and Data Source

Continuous…

For further information on this report, visit – https://www.wiseguyreports.com/reports/6089325-global-soy-dairy-protein-ingredient-market-research-report-2020

NOTE : Our team is studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

NORAH TRENT
Wise Guy Reports
+162 825 80070
email us here


Source: EIN Presswire

Acute Ischemic Stroke Diagnosis Market Market Growth, Trends, and Forecast Report with COVID-19 Analysis

Acute Ischemic Stroke Diagnosis Market is estimated to reach a market value of USD 2043.21 million by 2025 with the market estimated to grow at a CAGR of 5.12%

SEATTLE, WASHINGTON, UNITED STATES, December 3, 2020 /EINPresswire.com/ —
Market Overview

The acute ischemic stroke diagnosis market is also to witness healthy growth in the rising number of acute stroke patients and technological innovations in diagnostics. The prevalence of the disease is expected to rise in the future as well. Moreover, technological advancements in imaging have increased the accuracy of the devices, which have increased their demand in the market. This has further helped the market growth. Increasing demand has led to many developing regions in the world to better understand these diagnostic techniques. Hence many new products are being introduced to the market. In 2019, iSchemaView unveiled RAPID ANGIO, a complete neuroimaging solution for the angiography suite that integrates iSchemaView’s RAPID software with syngo DynaCT Multiphase from Siemens Healthineers. Moreover, the impact of COVID-19 has been minimal on the market. Acute Ischemic strokes require emergency diagnosis and follow-up procedures, as delay might be fatal for the patient.

Impact of COVID-19 on Acute Ischemic Stroke Diagnosis Market
Recent publications have raised the possibility that COVID-19 might increase the risk of ischemic stroke. Acute ischemic stroke was also reported during the earlier severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS) epidemics. Of 206 patients hospitalized for SARS in Singapore, five patients (2.4%) had large-artery strokes. Moreover, three had no traditional cerebrovascular risk factors, and four were critically ill, suggesting an association with the infection itself or its treatment. Potential causes of acute ischemic stroke in these patients included low ejection fraction from cardiac dysfunction, disseminated intravascular coagulopathy, and marantic (nonbacterial thrombotic) endocarditis. This has increased the demand for devices for diagnostic and research purposes, to better understand the cause and mechanism of these occurrences. Although visiting diagnostic centers or hospitals has been restricted as there is a risk of getting infected by the COVID-19 virus, most of the incidences of ischemic stroke are emergency cases that require immediate care. As a result, these cases are addressed in emergency situations as late care and diagnosis may be fatal for the patient. Hence, the impact of the COVID-19 outbreak is expected to be minimal on the market.

Request overview report @ https://www.globalmonitor.us/product/acute-ischemic-stroke-diagnosis-market

Market Dynamics
Rising number of Acute Stroke patients and technological innovations in Diagnostics devices are the major factors driving the growth of the market, while high cost of the instruments is the key factor challenging the growth of the market.

In 2017, the global prevalence of Ischemic stroke was 1.41%, with more than nearly 12 million being diagnosed in 2017. Moreover, the prevalence of the disease is expected to rise in the future as well. As per a report by the American Heart Association, the incidence of stroke in the United States is projected to be 3.48% in 2020, which is further expected to increase to 3.88% by 2030. In developing regions like Asia, the prevalence of ischemic stroke has increased over the years. As per a 2016 report by Nijasri C Suwanwela et al., Neurology India, a higher proportion of ischemic stroke in comparison to hemorrhagic stroke was found in Asian countries. The overall incidence of stroke in Asia is between 116 and 483/100,000 per year. Moreover, when compared to 1999, a 2-3-fold increase in the number of neurologists was obser ved in all countries. Additionally, the medical cost of stroke is also expected to rise in the future. As per the American Heart Association, the medical expense on stroke in the United States is expected to rise from USD 107.57 billion in 2020 to USD 184.13 billion by 2030. The increasing incidence of acuter ischemic stroke has increased the demand for diagnostic tests for the same, which has helped the market growth.

Request overview report @ https://www.globalmonitor.us/product/acute-ischemic-stroke-diagnosis-market

The diagnostic imaging machines vary in cost, which depends primarily on the strength and type of the scanner in use. With high strength, the scanners are able to provide highly detailed images, thereby raising the overall cost of machines. The overall cost of any imaging equipment is a huge investment for healthcare providers. Apart from the initial cost of investment for purchasing the imaging equipment, there are additional costs of around USD 8 million every year, which include its maintenance and high-cost for chilling the magnetic coils in the machine in case of an MRI.

Segmentation by Diagnostic Type
Rapid evaluation of acute stroke patients is expected to increase as the population ages and acute therapies expand. Imaging has become a significant aspect in the evaluation of acute ischemic stroke patients. Currently, non-contrast computed tomography (CT) remains one of the primary imaging modality for the initial evaluation of patients with suspected stroke.

Request overview report @ https://www.globalmonitor.us/product/acute-ischemic-stroke-diagnosis-market

A computed tomography (CT) scan uses a series of X-rays to create a detailed image of the brain. A CT scan is capable of showing any bleeding in the brain, an ischemic stroke, a tumor, and other conditions. A dye may be injected into the bloodstream to view the blood vessels in the neck and brain in greater detail (computerized tomography angiography). Moreover, advances have increased the overall sensitivity of CT to diagnose stroke as 64% and the specificity is 85%. As a result of these benefits, the demand for CT for acute ischemic stroke is high. Moreover, many companies are launching new and improved products in the market for a more efficient diagnosis. This has helped the market growth.

Segmentation by Geography
Stroke is the leading cause of severe long-term disability, and it is the fifth leading cause of death for Americans. According to the CDC, nearly 800,000 (approximately 795,000) people in the United States have strokes every year, with about three in the four being first-time strokes. Therefore, it is found that about 87% of strokes are classified as ischemic in the United States.

Bhanu Reddy
Global Monitor
+1 206-809-0882
email us here
Visit us on social media:
Twitter
LinkedIn


Source: EIN Presswire

A Parade of Forces United for Childhood Cancer Heroes

September 2020

Jeremiah watching Mystic Force Foundation’s Gold Ribbon Parade through his hospital room window at Nicklaus Children’s Hospital.

Stage IV Neuroblastoma Cancer warrior Kayson at the Mystic Force Foundation Parade in September 2020

Hope for our brave Hero Kayson

JJ lost both eyes to Retinoblastoma Cancer and continues to bring Hope to all children battling cancer. His sign says I'm worth more than 4% because our government only allocates 4% of NCI funds for Childhood Cancer Research. All our kids are worth more t

Hope for our Hero JJ

A monumental show of Hope, Love & Support for our bravest Heroes battling Childhood Cancer

HOLLYWOOD , FLORIDA, USA, December 3, 2020 /EINPresswire.com/ — Broward Sheriff’s Office Vehicles, South Florida Police Department Vehicles, Fire Trucks, a Gold Lamborghini, Broward Batman & the BatMobile, Childhood Cancer Families & Community Leaders Coming Together In
Love & Support for our Bravest Little Heroes
Despite the pandemic children continue to battle Childhood Cancer and fight for their lives. This Friday December 4th the Mystic Force Foundation will join forces with the Broward Sheriff’s Office, Police Departments from across South Florida, Fire Departments, community leaders, and families battling Childhood Cancer in a monumental show of love, unity and support for the bravest little Heroes battling the #1 disease killer of children in this country. The Parade will begin in Hollywood where the Gold Ribbon adorned vehicles will depart with lights & sirens blaring in an unprecedented show of Hope, Love & Solidarity in the fight against Childhood Cancer and drive past Joe DiMaggio Children’s Hospital then on to Salah Foundation Children’s Hospital at Broward Medical Center. This Parade is in Honor of 5 year old Jacob, the son of Corporal Kevin Schwartz of the Biscayne Park Police Department, who was recently diagnosed with Osteosarcoma cancer, and is dedicated to every child and family affected by Childhood Cancer.

Mystic Force Foundation consistently teams up with local Police Departments at events and special occasions throughout the year to bring joy and happiness to kids battling cancer. From Parades, to rides in Police Cars, to granting special ‘Wishes’, and ‘End Of Chemo’ celebrations, officers show children battling cancer and their families kindness, support, & love.
These Police Departments join the Foundation to remind families that they are never alone in their fight.

Friday December 4th
Meeting time: 10:30am
Target Store Hollywood
3251 Hollywood Boulevard . Hollywood, FL . 33021
(departure time approximately 11:00am)
Drive By – Joe DiMaggio Children’s Hospital
1005 Joe DiMaggio Drive . Hollywood, FL . 33021
(Continuing on to staging area)
Wells Fargo Bank
1710 S Andrews Avenue . Ft Lauderdale, FL . 33316
(departure time approximately 11:45am)
Drive By – Salah Children’s Hospital
1600 S Andrews Avenue . Ft Lauderdale, FL . 33316

For more information you may contact Silvia@MysticForceFoundation.com 305.726.1155 or
EstherReynolds1@gmail.com 786.897.1997

Press is invited to join us at 10:30am on the SW side of the Target Parking lot.
Masks required and adhering to strict social distancing guidelines.

The Mystic Force Foundation was founded in 2008 by Dr. Steven & Silvia Vanni after their then 4-year-old son, Salvatore, was diagnosed with Stage IV Neuroblastoma Cancer. Salvatore lost his battle with cancer in 2011 but his legacy continues to change the lives of all children battling this devastating disease. This year is the Foundation’s 12-year Anniversary of raising awareness and desperately needed funds for Childhood Cancer Research, as well as advocacy in Washington, DC, granting ‘Wishes’, delivering toys, holding in-patient hospital parties, and bringing Hope, Joy, Happiness and Smiles to the littlest Heroes battling Childhood Cancer. They are also celebrating the 2nd anniversary of The Heroes Hangout, the country’s first and only Childhood Cancer Haven dedicated solely to children battling cancer located in North Miami Beach. The Heroes Hangout is free to families, is sponsored by the Dante Law Firm and is 100% community supported.

Silvia Dominguez Vanni
Mystic Force Foundation
+1 305-726-1155
email us here
Visit us on social media:
Facebook
Twitter


Source: EIN Presswire

Healthcare Biometrics Market Growth, Trends, and Forecasts (2020-2026)

Globalmonitor

Globalmonitor

Global Healthcare Biometrics Market is expected to register 24.42% CAGR during 2019 to 2025

SEATTLE, WASHINGTON, UNITED STATES, December 3, 2020 /EINPresswire.com/ — Market Overview
Growing demand for efficient healthcare compliance and emergence of multimodal biometrics are the key trends in the global Biometrics market. The theft of critical data from government departments such as intelligence, law enforcement, defence, and finance can jeopardize national security. As a result, the adoption of biometric technologies such as DNA analysis and biometric technologies is high among the government sector, which is fueling the growth of the market.

Key technological developmental leading to commodification of biometrics, high adoption in the healthcare sector, and increased R&D spending by the healthcare companies are the major market drivers. High threat of cybersecurity attacks and strong competition from non-biometric substitutes are the key challenges hindering the growth of the market.

Request overview report @ https://www.globalmonitor.us/product/healthcare-biometrics-market

Segmentation by Product
Iris recognition is also popular for its accuracy and ease-of-use by patients in healthcare industry. Iris recognition segment is expected to have growing demand with ongoing situations such as contactless world. According to the Research Fellow and iris recognition technology expert from the Chinese Academy of Sciences (CAS) Institute of Automation Sun Zhenan believes unique characteristics such as the iris is more hygienic as it also does not have to involve physical touch in getting patient details. In order to cope with the iris recognition development, China has already created an iris biometrics database with information of 20 million people, developed by Beijing Municipal Public Security Bureau and Iris King.

In Nov 2019, Northwell Health stated that it is utilizing iris scanning biometrics technology from Right Patient with the high-resolution photograph that is taken additionally which can support facial recognition.

In Aug 2020, Eye Lock and CMI Tech have started mass production of Nano iXT biometric iris recognition reader for international market. nano iXT works on all types of Eye Lock readers and is fitted with various user-focused features such as large LCD touchscreen, dual auto-tilt cameras (iris and face biometrics), audible and visual user guidance, built-in HID card reader and multi-language support.

Request overview report @ https://www.globalmonitor.us/product/healthcare-biometrics-market

Segmentation by Geography
US holds the largest market share of healthcare biometrics market owing to increasing healthcare expenditure, and highly developed healthcare systems in the country. Increasing prevalence of chronic diseases, development of biologics and pharmaceutical drugs and devices, increasing patient compliance and patient safety will drive the growth of healthcare biometrics market in this country. The spurring technological advancements in IT healthcare in line with growth of the wearables market, and the capability to offer enhanced healthcare system drives the market growth across the United States. Accordingly, recent statistics estimates 25 percent of the adult population in the United States to be using a wearable device by 2022. Although there are many prospects in this market, challenges associated with FDA approvals, cyber security, and breaching of healthcare biometrics restrain the market growth. Various factors such as technological advancement, supportive regulatory environment and specialized IT expertise drive the growth of the market. New product launches and aggressive collaborative strategies adopted by major players would provide ample opportunity for the growth of the market.

Germany is the largest in the European IoT in healthcare market, due to high healthcare spending, government support, huge IT technical expertise followed by France and United Kingdom. Factors such as high skilled experts, technological advancements and new hub for drive the growth of the market. According to networking giant Cisco, Germany leads the world in implementing Internet of Things in the healthcare sector. Germany also has high adoption rate of wearable sensor devices among the population. Customer in the country are willingness to invest in their well-being and presence of advanced technologies will offer strong support for the healthcare biometrics market growth over the estimation period. The regulatory policies such as GDPR, to protect data security and integrities are estimated to boost the product adoption and demand for healthcare biometrics in Germany. Germany-based developers and manufacturers are capitalizing on the market share with increased industrialization and production of healthcare biometrics devices.

Request overview report @ https://www.globalmonitor.us/product/healthcare-biometrics-market

In Jul 2020, BioSec in partnership with IT security company Secobit, has launched palm vein biometrics for access control at German construction site. The biometric is only for those who attended an Occupational Safety and Health Training can access the site by showing their hands for authentication.

Bhanu Reddy
Global Monitor
+1 206-809-0882
email us here
Visit us on social media:
Twitter
LinkedIn


Source: EIN Presswire

Techcyte’s AI Digital Diagnostics Platform Receives CE-IVD Mark

Techcyte, the world leader in AI-based cellular diagnostics, has received the CE-IVD marking for its AI Digital Diagnostics platform.

OREM, UT, UNITED STATES, December 3, 2020 /EINPresswire.com/ — Techcyte, the world leader in AI-based cellular diagnostics, has received the CE-IVD marking for its AI Digital Diagnostics platform. The CE mark demonstrates that the Techcyte platform complies with European IVD regulations and can be used for diagnostic testing and to provide computer-assisted object labeling for quick diagnosis.

The Techcyte platform allows lab technicians and clinical pathologists to make a diagnosis using digital images. The Techcyte platform facilitates efficient remote diagnosis and collaboration at a time when clinics need it more than ever. The platform can display and analyze images from leading scanner manufacturers, such as Hamamatsu, Grundium, Motic, 3dHistech, Leica, etc.

Customers around the world use Techcyte’s platform and AI-based algorithms to perform fecal O&P tests, digital white-and-red blood cell differentials, cervical cytologies, bacteriology analysis, and mold-and-particulates air analyses. The platform is the only comprehensive platform that focuses on the entire workflow–including sample prep, scanning, case management, analysis, diagnosis, and reporting–and specializes in liquid and cellular-based sample types.

“The CE-IVD marking is a critical step to show that Techcyte not only complies with the European In Vitro Diagnostic Regulations, but that it is also dedicated to ensuring the quality and safety of our solution," said Techcyte’s European Managing Director, Troy Bankhead.

Digital AI-based diagnostics are helping labs that are struggling with skilled-labor shortages and increasing competitive pressures to provide results more efficiently. Techcyte solves these problems by increasing a lab’s accuracy and efficiency while reducing the time needed to deliver results and improving patient care.

In EU and EEA countries Techcyte® is CE marked under the EU's In Vitro Diagnostic Device Regulation 2017/746 for in vitro diagnostic use. In the USA, Japan, and other countries Techcyte is for research use only and is not for use in diagnostic procedures.

###
About Techcyte
Headquartered in Utah and Luxembourg, Techcyte, Inc. was founded in 2013 and is the world leader in AI-based cellular digital diagnostics. Techcyte's use of deep machine learning to perform automated analysis of whole slide microscopy images is revolutionizing digital diagnostics in research, environmental, human and animal health. Visit www.techcyte.com for more information.

Techcyte Media Contact:
Troy Bankhead, ‭+352 621 498 848‬, troy.bankhead@techcyte.com
Ben Cahoon, 888-878-3249, ben.cahoon@techcyte.com

Ben Cahoon
Techcyte, Inc.
+1 888-878-3249
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

China 3D Cardiac Mapping Market Acquisition, Covid 19 Analysis, Key Country And Regional Forecast To 2027

3D cardiac mapping is a procedure that is used to diagnose the origins of cardiac arrhythmias. This process uses an electrically sensitive catheter to map

PUNE, MAHARASHTRA, INDIA, December 3, 2020 /EINPresswire.com/ — growth of the China 3D cardiac mapping market is attributed to the prevalence of cardiac arrhythmias, rise in preference for minimally invasive procedures, and increase in geriatric population. However, high cost of 3D cardiac mapping issues hinder the market growth. On the contrary, rise in preference for 3D cardiac mapping is expected to provide significant profitable opportunities for manufacturers in the China 3D cardiac mapping market.

“China 3D Cardiac Mapping Market by application and end user: opportunity analysis and industry forecast, 2020–2027,” the China 3D cardiac mapping market was valued at $55.55 million in 2019 and is projected to reach $150.59 million by 2027, registering a CAGR of 12.8% from 2020 to 2027.

Download Free Sample Report@ https://www.alliedmarketresearch.com/request-sample/6882

Covid-19 Impact on the Global3D Cardiac Mapping Market:

3D Cardiac Mapping Market Report provides an overview of the market based on key parameters such as market size, sales, sales analysis and key drivers. The market size of the market is expected to grow on a large scale during the forecast period (2019-2026). This report covers the impact of the latest COVID-19 on the market. The coronavirus epidemic (COVID-19) has affected all aspects of life around the world. This has changed some of the market situation. The main purpose of the research report is to provide users with a broad view of the market. Initial and future assessments of rapidly.

Comprehensive competitive analysis and profiles of major market players such as Abbott Laboratories, Microport Scientific Corporation, Medtronic Plc, and Acutus Medical provided in this report.

The impact of the coronavirus pandemic and the lockdown it triggered is visible in various industries, including the China 3D cardiac mapping market. Furthermore, this disease predominantly affects the lungs, frequently leading to pneumonia and acute respiratory distress syndrome, adverse effects on the heart have also been observed. On the contrary it has been observed that there is prevalence of Novel coronavirus in patients suffering with conditions like arrhythmia. For this condition mainly 3D cardiac mapping is used. All these factors are anticipated to impact the china 3D cardiac mapping market as well in the future.

Rise in the number of cardiac arrhythmias patients in China and benefits of using advanced 3D cardiac mapping systems such electroanatomical mapping, basket catheter mapping, and real-time positional management (cardiac pathways) EP system over conventional products are expected to boost the growth of the China market. However, lack of awareness, less variability in products, and high cost in China are expected to hamper the market growth. On the contrary, rise in preference for 3D cardiac mapping is expected to provide significant profitable opportunities for manufacturers in the China 3D cardiac mapping market.

The geriatric population in China continues to grow at an exceptional rate and the proportion of elderly population is more prone to cardiovascular diseases. Incidences of cardiac arrhythmias in aged people are more as compared to adult population, owing to long life expectancy and life style modifications According to the China National Committee on Aging (CNCA), 2017, approximately 241 million people in China were aged 60 or above and it is estimated that by 2050 the number would rise to 487 million across China. Thus, alarming rise in prevalence of cardiac arrhythmias cases in China is expected to drive the growth of the China 3D cardiac mapping market.

Inquiry for Buying@ https://www.alliedmarketresearch.com/purchase-enquiry/6882

About Us:

Allied Market Research (AMR) is a market research and business-consulting firm of Allied Analytics LLP, based in Portland, Oregon. AMR offers market research reports, business solutions, consulting services, and insights on markets across 11 industry verticals. Adopting extensive research methodologies, AMR is instrumental in helping its clients to make strategic business decisions and achieve sustainable growth in their market domains. We are equipped with skilled analysts and experts, and have a wide experience of working with many Fortune 500 companies and small & medium enterprises.

Shadab Pathan
Allied Market Research
email us here
+1 800-792-5285


Source: EIN Presswire

Spanish Scientologists Rally to Help the Country Bring the Pandemic Under Control

In May, Scientology Volunteer Ministers of Madrid handed out educational booklets as the country began to reopen.

In May, Scientology Volunteer Ministers of Madrid handed out educational booklets as the country began to reopen.

Volunteer Ministers of Barcelona also took part in the prevention campaign.

Volunteer Ministers of Barcelona also took part in the prevention campaign.

Graphics are available to download to remind customers of the protocols.

Graphics are available to download to remind customers of the protocols.

These are available in Castilian Spanish and 20 additional languages.

These are available in Castilian Spanish and 20 additional languages.

With the number of new cases finally dropping in Spain, now is not the time to relax on prevention, say the Scientology Volunteer Ministers of Madrid.

LOS ANGELES, CALIFORNIA, UNITED STATES, December 3, 2020 /EINPresswire.com/ — In Madrid, Volunteer Ministers of the Church of Scientology of Spain are continuing their “Stay Well” campaign to reach out with proven protocols to help people stay well.

With the second wave of coronavirus finally abating—new cases down one third from last week—it is vital to continue prevention protocols. The danger when such an improvement takes place is that people can tend to neglect the very actions that caused the improvement. Now is not the time to change what is working, the volunteers say.

Madrid has canceled many traditional holiday events to prevent the spread of the virus. And the Scientology Volunteer Ministers backed this up by visiting local shops to remind them of the importance of prevention protocols.

In May, 135 Volunteer Ministers from Scientology Churches and Missions across Spain distributed 74,000 copies of educational booklets in their neighborhoods. These booklets contain vital information to prevent the spread of the virus.

As soon as the pandemic began, the most effective measures were researched for ensuring the safety of Scientology staff and parishioners, and these were implemented internationally as protocols under the direction of Scientology ecclesiastical leader Mr. David Miscavige.

To make this prevention information broadly available, the Church of Scientology published three educational booklets: How to Keep Yourself & Others Well, How to Protect Yourself & Others with a Mask & Gloves and How to Prevent the Spread of Illness with Isolation. All three booklets are available to be read or downloaded free of charge in 21 languages from the How to Stay Well Prevention Resource Center on the Scientology website.

The Church of Scientology Volunteer Ministers program is a religious social service created in the mid-1970s by Scientology Founder L. Ron Hubbard. It constitutes one of the world’s largest independent relief forces. A Volunteer Minister’s mandate is to be “a person who helps his fellow man on a volunteer basis by restoring purpose, truth and spiritual values to the lives of others.” Their creed: “A Volunteer Minister does not shut his eyes to the pain, evil and injustice of existence. Rather, he is trained to handle these things and help others achieve relief from them and new personal strength as well.”

Media Relations
Church of Scientology International
+1 323-960-3500
email us here

How To Keep Yourself & Others Healthy


Source: EIN Presswire